Quick Search 
Drugs of Today
Register or sign in

  
 
  
Drugs Today 2017, 53(12): 653
ISSN 1699-3993
e-ISSN 1699-4019
Copyright 2017 Clarivate
CCC: 1699-3993
DOI: 10.1358/dot.2017.53.12.2737934
 
 
Inotuzumab ozogamicin for the treatment of patients with acute lymphocytic leukemia
Choudhry, A., O'Brien, S.M.
 
 
Inotuzumab ozogamicin is an antibody-drug conjugate comprised of a humanized anti-CD22 monoclonal antibody conjugated to calicheamicin, a cytotoxic antibiotic agent. Inotuzumab ozogamicin binds to CD22-expressing tumor cells, resulting in apoptotic cell death. Based on the results of the pivotal, phase III INO-VATE trial in acute lymphoblastic leukemia (ALL), approval of inotuzumab ozogamicin was recently granted for the treatment of patients with relapsed or refractory ALL, a group that otherwise has a poor prognosis with standard chemotherapy. Several ongoing clinical trials are now testing whether outcomes can be further improved by combining inotuzumab ozogamicin with low-dose chemotherapy or by including inotuzumab ozogamicin in the front-line setting. In this article we discuss the preclinical, clinical and safety data of inotuzumab ozogamicin.


Full Text: PDF 
 
  



© Clarivate. All rights reserved.
Copyright NoticeTerms of UsePrivacy StatementCookie PolicyManage cookie preferences